Bal Pharma is an API and finished-dose manufacturer based in India. It holds 2 active US drug master files and 7 valid CEPs across a filed portfolio of 7 molecules. Its filings concentrate with NAFDAC (NG), MINSA (CR) and TMDA (TZ). Its GMP standing is certified by CDSCO (India), EMA and NAFDAC (NG). Customs aggregates show $22.4M of exports covering 1,090 molecules to 77 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Bangalore, United Arab Emirates | Not on file |
| Bangalore, India | Not on file |
| Bengaluru, India | Not on file |
| Rudrapur, India | Not on file |
| Bengaluru, India | Not on file |
| bengaluru 560099, India | Not on file |
1 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Gliclazide | EDQM, SFDA (Saudi Arabia) | 4 |
| Adapalene | EDQM, SFDA (Saudi Arabia) | 2 |
| Benzydamine | EDQM, SFDA (Saudi Arabia) | 2 |
| Bepotastine | US FDA | 2 |
| Amiloride | EDQM | 1 |
| Deferasirox | EDQM | 1 |
| Ebastine | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NAFDAC (NG) | 16 | 2 |
| MINSA (CR) | 9 | None |
| TMDA (TZ) | 9 | None |
| MCAZ (ZW) | 9 | None |
| ZAMRA (ZM) | 7 | None |
| EFDA (ET) | 3 | None |
| CDSCO (India) | None | 3 |
| EMA | None | 3 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $1.9M | 26 |
| 2025 | Not reported | $22.4M | 77 |
| 2024 | Not reported | $21.5M | 79 |
| 2023 | Not reported | $25.6M | 82 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Bal Pharma comes back tiered against every other supplier able to file there.
Start for free